SCHEMBL4728299

SCHEMBL4728299

COCCN(C)Cc1csc(NC(=O)NCc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 11/20 0.44
ROCK2 O75116 9/20 0.44
MAPK1 P28482 2/20 0.44
TSHR P16473 1/20 0.44
GCK P35557 1/20 0.42
ENPP2 Q13822 1/20 0.41
RAB9A P51151 1/20 0.40
AURKA O14965 1/20 0.40
DYRK3 O43781 1/20 0.40
PRKD3 O94806 1/20 0.40
PRKCG P05129 1/20 0.40
PRKACA P17612 1/20 0.40
RPS6KB1 P23443 1/20 0.40
MARK3 P27448 1/20 0.40
AKT1 P31749 1/20 0.40
CSNK1D P48730 1/20 0.40
CLK2 P49760 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
RPS6KA3 P51812 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779148 0.93 MEN1 (0.45) ROCK1ROCK2MAPK1GCKENPP2
Hydrochloric Acid SCHEMBL4956807 0.92 MEN1 (0.44) ROCK1ROCK2MAPK1GCKENPP2
SCHEMBL4957984 0.92 ENPP2 (0.46) ROCK1ROCK2MAPK1TSHRGCK
Hydrochloric Acid SCHEMBL4845630 0.91 ENPP2 (0.46) ROCK1ROCK2MAPK1TSHRGCK
SCHEMBL4777144 0.90 ROCK1 (0.43) ROCK1ROCK2MAPK1TSHRAURKA
SCHEMBL352216 0.89 ROCK1 (0.43) ROCK1ROCK2MAPK1TSHRENPP2
SCHEMBL4776692 0.89 ENPP2 (0.44) ROCK1ROCK2MAPK1TSHRENPP2
SCHEMBL4776684 0.89 ROCK1 (0.42) ROCK1ROCK2MAPK1TSHRAURKA
Hydrochloric Acid SCHEMBL4956924 0.89 ROCK1 (0.42) ROCK1ROCK2MAPK1TSHRAURKA
SCHEMBL4780576 0.88 ROCK1 (0.55) ROCK1ROCK2GCKRAB9AAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US claimed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US claimed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO claimed
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US disclosed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US disclosed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207703-A1 Antibacterial heterocyclic ureas UMPS, UROD, UGP2 ROCK1 4331/4885ROCK2 4405/4885MAPK1 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.